FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coppes, M. J.
Right arrow Articles by Williams, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coppes, M. J.
Right arrow Articles by Williams, B. R.

The FASEB Journal, Vol 7, 886-895, Copyright © 1993 by The Federation of American Societies for Experimental Biology

REVIEWS

The role of WT1 in Wilms tumorigenesis

MJ Coppes, CE Campbell and BR Williams
Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195.

Genetic alterations in tumor suppressor genes are believed to play an important role in the initiation of childhood and adult malignancies. Tumor-specific loss of heterozygosity for particular chromosomal regions has provided the starting point for the cloning of different tumor suppressor genes, including the Wilms tumor predisposing gene, WT1, at chromosome 11p13. This article reviews the pathology and genetics of Wilms tumor, the cloning of WT1, and the WT1 mutations reported thus far in 15 hereditary and nonhereditary Wilms tumors. The presence of constitutional WT1 mutations in 35 patients with the Denys- Drash syndrome (a syndrome consisting of nephropathy, intersex disorders, and Wilms tumor) is also described. To date, mutations in the WT1 gene have been found in less than 10% of Wilms tumors specimens examined and in greater than 95% of Denys-Drash patients. The possible significance of this observation with regard to both the cellular function of the WT1 protein and the involvement of alternative loci in the development of Wilms tumor is discussed.


This article has been cited by other articles:


Home page
 J. Med. Genet.Home page
R H Scott, C A Stiller, L Walker, and N Rahman
Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour
J. Med. Genet., September 1, 2006; 43(9): 705 - 715.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Kletzel
Why target the WT1 gene?
Blood, June 15, 2006; 107(12): 4578 - 4579.
[Full Text] [PDF]

Home page
 Mol. Pathol.Home page
J Alami, B R Williams, and H Yeger
Differential expression of E-cadherin and {beta} catenin in primary and metastatic Wilms's tumours
Mol. Pathol., August 1, 2003; 56(4): 218 - 225.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. A. Elisseeva, Y. Oka, A. Tsuboi, K. Ogata, F. Wu, E. H. Kim, T. Soma, H. Tamaki, M. Kawakami, Y. Oji, et al.
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
Blood, May 1, 2002; 99(9): 3272 - 3279.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. H. Laity, H. J. Dyson, and P. E. Wright
Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein
PNAS, October 24, 2000; 97(22): 11932 - 11935.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Oh, Y. Song, J. Yim, and T. K. Kim
The Wilms' Tumor 1 Tumor Suppressor Gene Represses Transcription of the Human Telomerase Reverse Transcriptase Gene
J. Biol. Chem., December 24, 1999; 274(52): 37473 - 37478.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Tajinda, J. Carroll, and C. T. Roberts Jr.
Regulation of Insulin-Like Growth Factor I Receptor Promoter Activity by Wild-Type and Mutant Versions of the WT1 Tumor Suppressor
Endocrinology, October 1, 1999; 140(10): 4713 - 4724.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child.Home page
A. Koziell and R. Grundy
Frasier and Denys-Drash syndromes: different disorders or part of a spectrum?
Arch. Dis. Child., October 1, 1999; 81(4): 365 - 369.
[Full Text]

Home page
 J. Biol. Chem.Home page
M. A. English and J. D. Licht
Tumor-associated WT1 Missense Mutants Indicate That Transcriptional Activation by WT1 Is Critical for Growth Control
J. Biol. Chem., May 7, 1999; 274(19): 13258 - 13263.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. W. Johnstone, J. Wang, N. Tommerup, H. Vissing, T. Roberts, and Y. Shi
Ciao 1 Is a Novel WD40 Protein That Interacts with the Tumor Suppressor Protein WT1
J. Biol. Chem., May 1, 1998; 273(18): 10880 - 10887.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. B. Silberstein, K. Van Horn, P. Strickland, C. T. Roberts Jr., and C. W. Daniel
Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer
PNAS, July 22, 1997; 94(15): 8132 - 8137.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. T. Cohen, S. A. Bossone, G. Zhu, G. A. McDonald, and V. P. Sukhatme
Sp1 Is a Critical Regulator of the Wilms' tumor-1 Gene
J. Biol. Chem., January 31, 1997; 272(5): 2901 - 2913.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
G Ryan, V Steele-Perkins, J. Morris, F. Rauscher, and G. Dressler
Repression of Pax-2 by WT1 during normal kidney development
Development, January 3, 1995; 121(3): 867 - 875.
[Abstract] [PDF]

Home page
 NEJMHome page
M. J. Coppes, D. A. Haber, and P. E. Grundy
Genetic Events in the Development of Wilms' Tumor
N. Engl. J. Med., September 1, 1994; 331(9): 586 - 590.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.